Portfolio of Oral Plasma Kallikrein Inhibitors Continues to Advance

 

From the KalVista Pharmaceuticals, Inc. operational and financial results for the fiscal first quarter ended July 31, 2017:

“We continue to make progress with our portfolio of oral plasma kallikrein inhibitors in pursuit of our goal of a best-in-class oral therapy for HAE,” said CEO Andrew Crockett. “We are completing the first-in-human trial of KVD818 and plan to evaluate final data and determine future development plans as we continue to advance our additional molecules. KVD900 remains on track to be our next candidate to enter clinical testing, with a regulatory filing before the end of 2017, and there will be at least one additional candidate entering the clinic in 2018.”

(Source: KalVista)

2017-09-16T03:09:52+00:00